The recommendation stems from successful Phase 3 clinical trials, marking a significant step for the biopharmaceutical company as it seeks to expand its reach. For patients struggling with atopic dermatitis—a chronic inflammatory condition affecting roughly 4% of the global adult population—the drug offers a potential alternative to existing regimens.
In section Market Quotes
Incyte’s Opzelura Nears EU Approval for Eczema Treatment
The European Medicines Agency has issued a positive recommendation for Opzelura, Incyte’s topical cream intended to treat moderate atopic dermatitis. Should the European Commission follow this guidance, the product would become the first steroid-free topical therapy available in the European Union for patients who have not responded to standard treatments.
Following the agency's opinion, the European Commission now holds the final authority to grant authorization. If approved, this would represent the second indication for Opzelura within the bloc, building on its existing clearance for treating non-segmental vitiligo in adults and adolescents. Investors reacted to the news with optimism, sending Incyte shares up 1.7% to $109.36 in premarket trading on the Nasdaq, extending a rally that has seen the stock gain 17% over the past three months.
Comments (0)
No comments yet. Be the first!